- Exhibit & Support
- Hotel & Travel
Despite the benefits of LDL-C lowering, many patients on statin therapy with elevated triglycerides remain at risk for cardiovascular disease. The unprecedented data from the VASCEPA cardiovascular outcomes trial, REDUCE-IT, and its potential impact on patient care is evaluated.
Speaker: Daniel E. Hilleman, PharmD, FCCP
Presented by Amarin Pharma, Inc.